ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN—trial)

[1] Chang S-J(2013)Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis Gynecol Oncol 130 493-498

[2] Hodeib M(2007)Cytoreductive surgery in ovarian cancer Cancer Imaging 7 210-215

[3] Chang J(2019)Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome Ann Surg Oncol 26 2943-2951

[4] Bristow RE(2018)Pelvic exenteration for gynecologic malignancies: postoperative complications and oncologic outcomes Actas Urol Esp 42 121-125

[5] Pomel C(2015)Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer Gynecol Oncol 137 401-405

[6] Jeyarajah A(2012)An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) Gynecol Oncol 124 10-14

[7] Oram D(2013)Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial J Clin Oncol 363 943-953

[8] Hall M(2010)Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 11 13-21

[9] Savvatis K(2007)Preoperative evaluation and preparation for anesthesia and surgery Hippokratia 140 15-21

[10] Nixon K(2016)Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer Gynecol Oncol 135 19-24

[1] Chang S-J(2013)Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis Gynecol Oncol 130 493-498

[2] Hodeib M(2007)Cytoreductive surgery in ovarian cancer Cancer Imaging 7 210-215

[3] Chang J(2019)Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome Ann Surg Oncol 26 2943-2951

[4] Bristow RE(2018)Pelvic exenteration for gynecologic malignancies: postoperative complications and oncologic outcomes Actas Urol Esp 42 121-125

[5] Pomel C(2015)Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer Gynecol Oncol 137 401-405

[6] Jeyarajah A(2012)An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) Gynecol Oncol 124 10-14

[7] Oram D(2013)Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial J Clin Oncol 363 943-953

[8] Hall M(2010)Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 11 13-21

[9] Savvatis K(2007)Preoperative evaluation and preparation for anesthesia and surgery Hippokratia 140 15-21

[10] Nixon K(2016)Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer Gynecol Oncol 135 19-24